News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
293,281 Results
Type
Article (16734)
Company Profile (227)
Press Release (276315)
Multimedia
Podcasts (110)
Webinars (12)
Section
Business (90679)
Career Advice (169)
Deals (13470)
Drug Delivery (49)
Drug Development (51065)
Employer Resources (31)
FDA (5960)
Job Trends (5208)
News (145817)
Policy (10098)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (959)
Accelerated approval (34)
ADA (33)
Adcomms (16)
Allergies (118)
Alliances (21780)
ALS (178)
Alzheimer's disease (1206)
Antibody-drug conjugate (ADC) (454)
Approvals (6297)
Artificial intelligence (406)
ASCO (221)
Autoimmune disease (303)
Automation (16)
Bankruptcy (108)
Best Places to Work (4564)
BIO (54)
BIOSECURE Act (6)
Biosimilars (139)
BioSpace Insights (71)
Biotechnology (176)
Bladder cancer (128)
Brain cancer (60)
Breast cancer (453)
Cancer (4344)
Cardiovascular disease (323)
Career advice (162)
Career pathing (13)
CAR-T (300)
CDC (8)
Celiac Disease (1)
Cell therapy (789)
Cervical cancer (25)
Clinical research (45585)
Collaboration (1587)
Commercialization (4)
Company closure (3)
Compensation (853)
Complete response letters (68)
COVID-19 (1134)
CRISPR (116)
C-suite (877)
Cystic fibrosis (125)
Data (6299)
Denatured (23)
Depression (126)
Dermatology (73)
Diabetes (356)
Diagnostics (1503)
Digital health (19)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (313)
Drug pricing (54)
Drug shortages (3)
Duchenne muscular dystrophy (311)
Earnings (33315)
Editorial (36)
Employer branding (4)
Employer resources (29)
Events (54020)
Executive appointments (747)
FDA (8399)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (24)
Frontotemporal dementia (32)
Funding (1322)
Gene editing (241)
Generative AI (41)
Gene therapy (646)
GLP-1 (587)
Government (1194)
Grass and pollen (3)
Guidances (179)
Healthcare (6747)
Hematology (118)
HIV (31)
Huntington's disease (61)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (103)
Immunology and inflammation (260)
Immuno-oncology (88)
Indications (152)
Infectious disease (1298)
Inflammatory bowel disease (188)
Inflation Reduction Act (10)
Influenza (61)
Intellectual property (231)
Interviews (20)
IPO (7400)
IRA (13)
Job creations (871)
Job search strategy (136)
JPM (41)
Kidney cancer (11)
Labor market (36)
Layoffs (266)
Leadership (15)
Legal (1411)
Licensing (9)
Liver cancer (48)
Longevity (26)
Lung cancer (582)
Lymphoma (335)
Machine learning (35)
Management (7)
Manufacturing (589)
Marketing (9)
MASH (170)
Medical affairs (1)
Medical device (2743)
Medtech (2779)
Mergers & acquisitions (6880)
Metabolic disorders (984)
mRNA (180)
Multiple sclerosis (133)
NASH (14)
Neurodegenerative disease (375)
Neuropsychiatric disorders (91)
Neuroscience (2513)
Neurotech (1)
NextGen: Class of 2026 (2042)
Non-profit (888)
Now hiring (42)
Obesity (436)
Opinion (146)
Ovarian cancer (199)
Pain (144)
Pancreatic cancer (258)
Parkinson's disease (330)
Partnered (14)
Patents (437)
Patient recruitment (621)
Peanut (51)
People (27523)
Pharmaceutical (29)
Pharmacy benefit managers (6)
Phase 1 (16134)
Phase 2 (21183)
Phase 3 (13375)
Pipeline (7151)
Policy (108)
Postmarket research (889)
Preclinical (6882)
Press Release (30)
Prostate cancer (218)
Psychedelics (74)
Radiopharmaceuticals (302)
Rare diseases (998)
Real estate (1462)
Recruiting (12)
Regulatory (10942)
Reports (25)
Research institute (998)
Resumes & cover letters (20)
Rett syndrome (42)
RNA editing (31)
RSV (25)
Schizophrenia (155)
Series A (257)
Series B (183)
Service/supplier (1)
Sickle cell disease (98)
Special edition (21)
Spinal muscular atrophy (128)
Sponsored (18)
Startups (2037)
State (1)
Stomach cancer (5)
Supply chain (41)
Tariffs (19)
The Weekly (85)
Vaccines (424)
Venture capital (98)
Weight loss (233)
Women's health (50)
Worklife (2)
Date
Today (50)
Last 7 days (369)
Last 30 days (1420)
Last 365 days (18058)
2026 (11501)
2025 (18094)
2024 (20468)
2023 (22418)
2022 (26822)
2021 (27806)
2020 (23366)
2019 (16254)
2018 (11750)
2017 (13751)
2016 (11845)
2015 (14361)
2014 (10397)
2013 (7493)
2012 (7540)
2011 (7712)
2010 (7977)
Location
Africa (162)
Alabama (79)
Alaska (2)
Arizona (92)
Arkansas (6)
Asia (19003)
Australia (3274)
California (9242)
Canada (2337)
China (1146)
Colorado (331)
Connecticut (345)
Delaware (319)
Europe (40933)
Florida (1210)
Georgia (267)
Hawaii (3)
Idaho (18)
Illinois (564)
India (57)
Indiana (220)
Iowa (9)
Japan (341)
Kansas (89)
Kentucky (11)
Louisiana (17)
Maine (14)
Maryland (949)
Massachusetts (7364)
Michigan (131)
Minnesota (325)
Mississippi (3)
Missouri (38)
Montana (17)
Nebraska (6)
Nevada (51)
New Hampshire (22)
New Jersey (2089)
New Mexico (13)
New York (2287)
North Carolina (1077)
North Dakota (7)
Northern California (4731)
Ohio (230)
Oklahoma (11)
Oregon (25)
Pennsylvania (1687)
Puerto Rico (12)
Rhode Island (26)
South America (220)
South Carolina (13)
Southern California (3732)
Tennessee (62)
Texas (1277)
United States (30521)
Utah (128)
Virginia (186)
Washington D.C. (37)
Washington State (755)
West Virginia (1)
Wisconsin (67)
293,281 Results for "eureka therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Eureka’s ARTEMIS® CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine
November 14, 2025
·
4 min read
Press Releases
Eureka Therapeutics Adds Stanford Liver Cancer Expert Dr. Samuel So to Scientific Advisory Board
August 6, 2025
·
2 min read
Press Releases
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors
August 13, 2025
·
1 min read
Drug Development
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
Eureka Therapeutics, Inc. today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
March 18, 2024
·
2 min read
Business
Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers
Eureka Therapeutics, Inc. today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
April 2, 2024
·
3 min read
Business
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
Eureka Therapeutics, Inc. today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS ® T-cell receptor platform.
March 14, 2023
·
2 min read
Anaut Announces Japanese Regulatory Approval of AI-Powered Surgical Visualization Tool, Eureka α
Anaut Inc., a pioneering developer in surgical support software led by CEO Dr. Nao Kobayashi, announced regulatory approval of its groundbreaking medical device, “Eureka α”.
May 2, 2024
·
3 min read
Drug Development
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics, Inc. today announced that the California Institute for Regenerative Medicine (CIRM) awarded the Company a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer.
June 6, 2023
·
3 min read
Press Releases
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
July 21, 2026
·
7 min read
Business
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS ® T Cell Therapy for Neuroblastoma.
October 18, 2022
·
2 min read
1 of 29,329
Next
